Matthew Doty, DO
Interventional Pain Medicine · Oroville, CANPI 1538528674
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,988 of the $3,148 with a category attached, or 63.1%. 13 manufacturers reported payments, led by Abbott at 36.1% of the total. Reporting peaked in 2021 at $1,384 and has fallen 83.5% since, to $229 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in CA, where the typical reported total is $3,134.
Across 30 payments — averaging $104.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Spinal Simplicity, LLC$845
- Boston Scientific$311
- Medtronic$284
- Relievant Medsystems, Inc.$131
- Nalu Medical, Inc.$125
- plus $317 from 7 others
Across 430 payments — averaging $3120.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$495K
- Takeda Pharmaceuticals U.S.A., Inc.$328K
- Chiesi USA, Inc.$223K
- Sage Therapeutics, LLC$160K
- Pfizer$69K
- Abbott$45K
- plus $21K from 1 others
What the payments were for
- Travel & lodging$1,98863%
- Food & beverage$1,16037%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 12 | $1,135 |
| Spinal Simplicity, LLC | 1 | $845 |
| Boston Scientific | 3 | $311 |
| Medtronic | 5 | $284 |
| Relievant Medsystems, Inc. | 1 | $131 |
| Nalu Medical, Inc. | 1 | $125 |
| Abiomed | 1 | $124 |
| Novo Nordisk | 1 | $80 |
| Stryker | 1 | $27 |
| Verona Pharma, Inc. | 1 | $27 |
| Genentech USA, Inc. | 1 | $21 |
| Amgen | 1 | $19 |
| GSK | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,148 in reported general payments places this provider in the 50th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 17 | $1,090 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 118 | $605 |
| Cyclobenzaprine Hcl | 101 | $439 |
| Gabapentin | 30 | $325 |
| Meloxicam | 128 | $154 |
| Lorazepam | 34 | $37 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Oroville
- Michael Verdolinla Mesa$507K
- Tim LeierRancho Mirage$449K
- Jonathan GrossmanVisalia$404K
- Kasra MaasumiRancho Santa Margarita$388K
- Andrew GermanovichRancho Mirage$333K
- David LeeYorba Linda$257K
- Standiford HelmOrange$254K
- Patrick BuchananCamarillo$219K
- Chau VuSanta Rosa$141K
- Phillip LimBuena Park$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.